Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$10.80 -0.9%	$14.34	$6.59 ▼ $21.00	$491.88M	1.19	469,195 shs	505,686 shs
CNMD CONMED	$56.53 -0.1%	$55.09	$46.00 ▼ $78.58	$1.75B	1.19	443,291 shs	277,659 shs
ENOV Enovis	$31.59 -0.7%	$33.53	$29.13 ▼ $49.83	$1.80B	1.71	814,682 shs	1.52 million shs
LMAT LeMaitre Vascular	$83.40 +1.0%	$83.75	$71.42 ▼ $109.58	$1.88B	0.86	168,545 shs	119,039 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-4.05%	-0.55%	-34.93%	-38.66%	+58.89%
CNMD CONMED	-0.60%	-1.12%	-0.71%	-4.42%	-27.25%
ENOV Enovis	+3.95%	-2.30%	-6.88%	-14.19%	-32.92%
LMAT LeMaitre Vascular	-0.37%	+1.90%	+2.62%	+0.07%	+6.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	3.0311 of 5 stars	3.5	3.0	0.0	0.0	3.2	2.5	0.6
CNMD CONMED	4.3953 of 5 stars	2.2	1.0	2.5	4.3	3.4	0.8	3.1
ENOV Enovis	2.5505 of 5 stars	3.4	1.0	0.0	0.0	2.1	1.7	1.9
LMAT LeMaitre Vascular	2.4521 of 5 stars	2.2	1.0	3.3	0.0	2.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$22.20	105.56% Upside
CNMD CONMED	2.40	Hold	$62.20	10.04% Upside
ENOV Enovis	2.80	Moderate Buy	$58.00	83.58% Upside
LMAT LeMaitre Vascular	2.33	Hold	$97.83	17.31% Upside

Current Analyst Ratings Breakdown

Latest AXGN, LMAT, ENOV, and CNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
5/13/2025	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
5/9/2025	ENOV Enovis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$62.00 ➝ $55.00
5/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $57.00
5/1/2025	CNMD CONMED	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$70.00 ➝ $58.00
5/1/2025	CNMD CONMED	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $57.00
5/1/2025	CNMD CONMED	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$91.00 ➝ $61.00
4/28/2025	CNMD CONMED	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$75.00 ➝ $55.00
4/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
4/2/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
3/17/2025	AXGN AxoGen	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$194.52M	2.53	N/A	N/A	$2.22 per share	4.86
CNMD CONMED	$1.32B	1.33	$6.19 per share	9.13	$31.15 per share	1.81
ENOV Enovis	$2.15B	0.84	$4.61 per share	6.86	$62.66 per share	0.50
LMAT LeMaitre Vascular	$226.26M	8.33	$1.48 per share	56.52	$13.38 per share	6.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$21.72M	-$0.15	N/A	N/A	N/A	-7.91%	-14.91%	-7.49%	8/14/2025 (Estimated)
CNMD CONMED	$132.42M	$3.80	13.33	11.15	1.83	10.13%	14.31%	5.64%	7/30/2025 (Estimated)
ENOV Enovis	-$33.26M	-$13.95	N/A	9.90	N/A	-5.95%	4.39%	2.80%	8/6/2025 (Estimated)
LMAT LeMaitre Vascular	$30.10M	$1.98	45.57	38.43	2.22	19.40%	13.15%	11.47%	7/30/2025 (Estimated)

Latest AXGN, LMAT, ENOV, and CNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/30/2025	Q1 2025	CNMD CONMED	$0.81	$0.95	+$0.14	$0.19	$313.38 million	$321.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
CNMD CONMED	$0.80	1.42%	N/A	21.05%	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.96%	+13.30%	40.40%	14 Years

Latest AXGN, LMAT, ENOV, and CNMD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/21/2025	CNMD CONMED	quarterly	$0.20	1.34%	6/13/2025	6/13/2025	7/3/2025
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.67	3.74	2.47
CNMD CONMED	0.94	2.30	1.06
ENOV Enovis	0.40	2.27	1.12
LMAT LeMaitre Vascular	N/A	7.74	5.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
CNMD CONMED	N/A
ENOV Enovis	98.45%
LMAT LeMaitre Vascular	84.64%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
CNMD CONMED	3.10%
ENOV Enovis	2.70%
LMAT LeMaitre Vascular	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	45.54 million	40.93 million	Optionable
CNMD CONMED	4,100	30.94 million	28.81 million	Optionable
ENOV Enovis	6,800	57.12 million	55.49 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.06 million	Optionable

AXGN, LMAT, ENOV, and CNMD Headlines

Recent News About These Companies

Two Sigma Investments LP Has $2.43 Million Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

June 1, 2025 | marketbeat.com

Nuveen Asset Management LLC Decreases Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

June 1, 2025 | marketbeat.com

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Intrinsic Value Is Potentially 17% Below Its Share Price

May 31, 2025 | finance.yahoo.com

Kings Path Partners LLC Reduces Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 31, 2025 | marketbeat.com

Two Sigma Advisers LP Decreases Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 31, 2025 | marketbeat.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stake Boosted by Bank of America Corp DE

May 29, 2025 | marketbeat.com

Squarepoint Ops LLC Sells 16,612 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 27, 2025 | marketbeat.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stake Boosted by Millennium Management LLC

May 27, 2025 | marketbeat.com

Deutsche Bank AG Purchases 5,747 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 26, 2025 | marketbeat.com

LeMaitre Vascular’s SWOT analysis: niche market leader faces valuation hurdles

May 24, 2025 | uk.investing.com

D. E. Shaw & Co. Inc. Decreases Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 24, 2025 | marketbeat.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Moderate Buy" from Brokerages

May 24, 2025 | marketbeat.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by AWM Investment Company Inc.

May 23, 2025 | marketbeat.com

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre Sells 4,399 Shares

May 21, 2025 | insidertrades.com

Janus Henderson Group PLC Purchases 15,892 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 20, 2025 | marketbeat.com

Ameriprise Financial Inc. Sells 60,418 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 19, 2025 | marketbeat.com

Graham Capital Management L.P. Makes New Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 18, 2025 | marketbeat.com

LMAT Q1 Earnings Call: Sales Growth Outpaces Expectations, Margin Pressures Addressed

May 16, 2025 | msn.com

3,045 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Purchased by Centiva Capital LP

May 15, 2025 | marketbeat.com

Balyasny Asset Management L.P. Invests $3.09 Million in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 14, 2025 | marketbeat.com

Northern Trust Corp Raises Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

May 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN, LMAT, ENOV, and CNMD Company Descriptions

AxoGen NASDAQ:AXGN

$10.80 -0.10 (-0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$11.29 +0.49 (+4.54%)

As of 04:15 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

CONMED NYSE:CNMD

$56.53 -0.04 (-0.08%)

Closing price 03:59 PM Eastern

Extended Trading

$56.59 +0.06 (+0.11%)

As of 04:33 PM Eastern

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Enovis NYSE:ENOV

$31.59 -0.24 (-0.74%)

Closing price 03:59 PM Eastern

Extended Trading

$31.61 +0.02 (+0.05%)

As of 04:47 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

LeMaitre Vascular NASDAQ:LMAT

$83.40 +0.85 (+1.03%)

Closing price 04:00 PM Eastern

Extended Trading

$83.46 +0.06 (+0.07%)

As of 04:04 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time